Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage

AIDS

Volumn 24, Issue 8, 2010, Pages 1231-1233

  Moreno, Ana ^a   Quereda, Carmen ^a   Fortún, Jesús ^a   Bárcena, Rafael ^b   Pérez Elías, María J ^a   Casado, José L ^a   Rodríguez Sagrado, Miguel A ^c   Mateos, María L ^a   Blesa, Carlos ^b   Moreno, Santiago ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Services of Liver Gastroenterology   (Spain)

^c Services of Pharmacy   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; PEGINTERFERON; RALTEGRAVIR; RIBAVIRIN; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ANEMIA; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEASIBILITY STUDY; GASTROINTESTINAL DISEASE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LETTER; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LIVER TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 77951817362     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328336e9b3     Document Type: Letter

References (13)

1. Issentress (raltegravir) [package insert]. Whitehouse Station, New Jersey: Merck, 2008.
2. Hicks C, Gulick RM. Raltegravir: the first HIV Type 1 integrase inhibitor. Clin Infect Dis 2009; 48:931-939.
3. Moreno A, Barcena R, Quereda C, Casado JL, Perez-Eĺ?as MJ, Fortun J, et al. Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation. AIDS 2008; 22:547-548. (Pubitemid 351317304)
4. Tricot L, Teicher E, Peytavin G, Zucman D, Conti F, Calmus Y, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009; 9:1-7.
5. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
6. Lennox JL, Dejesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-nä?ve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796-806.
7. Perrone C. Antiviral hepatitis and antiretroviral drug interactions. J Hepatol 2006; 44 (Suppl 1):S119-S125. (Pubitemid 43053887)
8. Singal AK, Anand BS. Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review. World J Gastroenterol 2009; 15:3713-3724.
9. Carrión JA, Martinez-Bauer E, Crespo G, Raḿ?rez S, Pérez del Pulgar S, Garć?a-Valdecasas JC, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrho-tic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50:719-728.
10. Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology 2002; 36:S185-S194.
11. Berenguer J, Alvarez-Pellicer J, Miralles P, López-Aldeguer J, Von Wichmann MA, Quereda C, et al., The GESIDA3603/5607 Study Group. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50:407-413.
12. Dore GJ, Torriani FJ, Rodriguez-Torres M, Brau N, Sulkowski M, Lamoglia RS, et al. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection. AIDS 2007; 21:1555-1559. (Pubitemid 47075476)
13. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006; 12:1192-1204. (Pubitemid 44194586)